Ajanta Pharma Limited (AJANTPHARM.NS)
INR 2876.45
(-0.56%)
INR 2876.45
(-0.56%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 352.8 Million INR | -0.98% |
| 2022 | 356.3 Million INR | 42.35% |
| 2021 | 250.3 Million INR | -20.18% |
| 2020 | 313.6 Million INR | -58.16% |
| 2019 | 749.6 Million INR | 108.45% |
| 2018 | 359.6 Million INR | 1897.78% |
| 2017 | 18 Million INR | -73.57% |
| 2016 | 68.1 Million INR | -92.67% |
| 2015 | 929.3 Million INR | 28.39% |
| 2014 | 723.8 Million INR | -44.53% |
| 2013 | 1.3 Billion INR | 4.52% |
| 2012 | 1.24 Billion INR | 64.07% |
| 2011 | 760.89 Million INR | -60.09% |
| 2010 | 1.9 Billion INR | -16.38% |
| 2009 | 2.27 Billion INR | -8.89% |
| 2008 | 2.5 Billion INR | 44.18% |
| 2007 | 1.73 Billion INR | 49.13% |
| 2006 | 1.16 Billion INR | 18.3% |
| 2005 | 983.65 Million INR | 1.47% |
| 2004 | 969.42 Million INR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2024 Q2 | 24.2 Million INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 352.8 Million INR | 0.0% |
| 2023 FY | 352.8 Million INR | -0.98% |
| 2023 Q2 | 330.2 Million INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q2 | 284.8 Million INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 356.3 Million INR | 42.35% |
| 2022 Q4 | 356.3 Million INR | 0.0% |
| 2021 Q4 | 250.3 Million INR | 0.0% |
| 2021 FY | 250.3 Million INR | -20.18% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 269.1 Million INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 FY | 313.6 Million INR | -58.16% |
| 2020 Q4 | 313.6 Million INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 244.4 Million INR | 0.0% |
| 2019 Q4 | 749.6 Million INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 755.1 Million INR | 0.0% |
| 2019 FY | 749.6 Million INR | 108.45% |
| 2019 Q3 | - INR | -100.0% |
| 2018 FY | 359.6 Million INR | 1897.78% |
| 2018 Q4 | 359.6 Million INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 6.7 Million INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 FY | 18 Million INR | -73.57% |
| 2017 Q4 | 18 Million INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 10.3 Million INR | 0.0% |
| 2016 Q4 | 68.1 Million INR | 0.0% |
| 2016 FY | 68.1 Million INR | -92.67% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q2 | 255 Million INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q4 | 929.3 Million INR | 0.0% |
| 2015 FY | 929.3 Million INR | 28.39% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q2 | 431.2 Million INR | 0.0% |
| 2014 FY | 723.8 Million INR | -44.53% |
| 2014 Q4 | 723.8 Million INR | 0.0% |
| 2014 Q1 | - INR | 0.0% |
| 2013 FY | 1.3 Billion INR | 4.52% |
| 2012 FY | 1.24 Billion INR | 64.07% |
| 2011 FY | 760.89 Million INR | -60.09% |
| 2010 FY | 1.9 Billion INR | -16.38% |
| 2009 FY | 2.27 Billion INR | -8.89% |
| 2008 FY | 2.5 Billion INR | 44.18% |
| 2007 FY | 1.73 Billion INR | 49.13% |
| 2006 FY | 1.16 Billion INR | 18.3% |
| 2005 FY | 983.65 Million INR | 1.47% |
| 2004 FY | 969.42 Million INR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Sigachi Industries Limited | 1.43 Billion INR | 75.338% |
| Ind-Swift Limited | 10.13 Billion INR | 96.521% |
| Bajaj HealthCare Limited | 3.32 Billion INR | 89.4% |
| Sakar Healthcare Limited | 793.51 Million INR | 55.54% |
| Aurobindo Pharma Limited | 66.47 Billion INR | 99.469% |
| Innova Captab Limited | 2.45 Billion INR | 85.606% |
| Divi's Laboratories Limited | 30 Million INR | -1076.0% |
| AstraZeneca Pharma India Limited | 45.98 Million INR | -667.257% |
| Morepen Laboratories Limited | 289.99 Million INR | -21.659% |
| Mankind Pharma Limited | 2.07 Billion INR | 82.971% |
| Sequent Scientific Limited | 4.87 Billion INR | 92.766% |
| Wanbury Limited | 1.16 Billion INR | 69.713% |
| Laurus Labs Limited | 25.77 Billion INR | 98.631% |
| Nectar Lifesciences Limited | 6.35 Billion INR | 94.449% |
| Glenmark Life Sciences Limited | 171.48 Million INR | -105.738% |
| Alembic Limited | 91.5 Million INR | -285.574% |
| Hikal Limited | 8.17 Billion INR | 95.685% |
| Alembic Pharmaceuticals Limited | 5.13 Billion INR | 93.125% |
| Neuland Laboratories Limited | 953.89 Million INR | 63.015% |
| J. B. Chemicals & Pharmaceuticals Limited | 3.77 Billion INR | 90.658% |
| Glenmark Pharmaceuticals Limited | 12.3 Billion INR | 97.134% |
| IOL Chemicals and Pharmaceuticals Limited | 327.6 Million INR | -7.692% |
| Themis Medicare Limited | 957.92 Million INR | 63.17% |
| RPG Life Sciences Limited | - INR | -Infinity% |
| Zydus Lifesciences Limited | 8.04 Billion INR | 95.613% |
| Lupin Limited | 29.21 Billion INR | 98.793% |
| Amrutanjan Health Care Limited | 17.28 Million INR | -1941.312% |
| Wockhardt Limited | 23.56 Billion INR | 98.503% |
| Vaishali Pharma Limited | 134.91 Million INR | -161.492% |
| Aarti Pharmalabs Limited | 2.85 Billion INR | 87.632% |
| Jagsonpal Pharmaceuticals Limited | 89.41 Million INR | -294.587% |
| Jubilant Pharmova Limited | 36.64 Billion INR | 99.037% |
| FDC Limited | 205.18 Million INR | -71.942% |
| Dr. Reddy's Laboratories Limited | 20.02 Billion INR | 98.238% |
| Kilitch Drugs (India) Limited | 316.46 Million INR | -11.482% |
| Eris Lifesciences Limited | 27.81 Billion INR | 98.732% |
| Venus Remedies Limited | 413.3 Million INR | 14.638% |
| ZIM Laboratories Limited | 1.08 Billion INR | 67.581% |
| Bliss GVS Pharma Limited | 998.4 Million INR | 64.663% |
| Par Drugs and Chemicals Limited | - INR | -Infinity% |
| Caplin Point Laboratories Limited | 19.7 Million INR | -1690.863% |
| Shilpa Medicare Limited | 9.37 Billion INR | 96.236% |
| Albert David Limited | 33.24 Million INR | -961.308% |
| Hester Biosciences Limited | 2.44 Billion INR | 85.563% |
| Suven Pharmaceuticals Limited | 649.96 Million INR | 45.72% |
| Solara Active Pharma Sciences Limited | 10.11 Billion INR | 96.512% |
| Gufic Biosciences Limited | 3.32 Billion INR | 89.403% |
| Windlas Biotech Limited | 36.41 Million INR | -868.965% |
| Procter & Gamble Health Limited | 95.6 Million INR | -269.038% |
| Aarey Drugs & Pharmaceuticals Limited | 313.52 Million INR | -12.528% |
| Mangalam Drugs & Organics Limited | 984.92 Million INR | 64.18% |
| Granules India Limited | 13.15 Billion INR | 97.317% |
| Aarti Drugs Limited | 5.64 Billion INR | 93.748% |
| Bal Pharma Limited | 1.39 Billion INR | 74.737% |
| Alkem Laboratories Limited | 14.18 Billion INR | 97.513% |
| Sun Pharmaceutical Industries Limited | 32.73 Billion INR | 98.922% |
| Lincoln Pharmaceuticals Limited | 10.66 Million INR | -3207.087% |
| Medicamen Biotech Limited | 308.17 Million INR | -14.482% |
| Unichem Laboratories Limited | 2.47 Billion INR | 85.746% |
| Bafna Pharmaceuticals Limited | 243.89 Million INR | -44.654% |
| Biofil Chemicals and Pharmaceuticals Limited | 4.38 Million INR | -7938.278% |
| Valiant Laboratories Limited | 767.08 Million INR | 54.008% |
| Orchid Pharma Limited | 1.35 Billion INR | 73.902% |
| Medico Remedies Limited | 80.5 Million INR | -338.239% |
| Ind-Swift Laboratories Limited | 166.21 Million INR | -112.254% |
| Ipca Laboratories Limited | 14.38 Billion INR | 97.547% |
| Brooks Laboratories Limited | 56.41 Million INR | -525.321% |
| Syncom Formulations (India) Limited | 724.86 Million INR | 51.329% |
| Piramal Enterprises Limited | 535.85 Billion INR | 99.934% |
| Torrent Pharmaceuticals Limited | 40.22 Billion INR | 99.123% |
| NATCO Pharma Limited | 3.71 Billion INR | 90.496% |
| Suven Life Sciences Limited | 7.09 Million INR | -4871.115% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 81.761% |
| Strides Pharma Science Limited | 25.16 Billion INR | 98.598% |
| Indoco Remedies Limited | 6.71 Billion INR | 94.75% |
| Alpa Laboratories Limited | 52.46 Million INR | -572.448% |
| Lasa Supergenerics Limited | 220.76 Million INR | -59.81% |
| Sun Pharma Advanced Research Company Limited | 611.5 Million INR | 42.306% |